logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics enrolls last patient in Phase 2B dose-ranging study of lead drug ATB-346

The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis pain compared to a placebo in 360 patients

Antibe Therapeutics, Inc. - Antibe Therapeutics enrolls last patient in Phase 2B dose-ranging, efficacy study of lead drug ATB-346
The last patient has been enrolled and is on treatment, and the company expects the release of top-line results within six weeks.

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) said Friday that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe’s lead drug, ATB-346.

The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis pain compared to a placebo in 360 patients.

In a statement, the Toronto-based company said the final patients will be on treatment for two weeks, followed by a two-week monitoring period and analysis of the primary endpoint data. The primary endpoint in the study tracks the change in osteoarthritis knee pain in patients taking ATB-346, versus placebo as measured by the WOMAC subscale pain score, considered the gold standard in pain assessment for arthritis trials.

READ: Antibe Therapeutics reports positive progress in Phase 2B trials of ATB-346

Patients have been randomized to placebo or one of three doses of ATB-346 administered once daily: 150 mg, 200 mg or 250 mg, said the company.

The company anticipates the release of top-line results within six weeks.

ATB-346 targets acute and chronic pain associated with osteoarthritis. Currently in Phase 2 trials, the drug is a naproxen-derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than typical NSAID usage.

Antibe develops safer, non-addictive medicines for pain and inflammation. The company’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. In addition to ATB-346, designed to target the need for a safer, non-addictive drug for chronic pain, the company’s second pipeline drug ATB-352, targets the need for a non-addictive analgesic for treating post-surgical pain. ATB-340, meanwhile, is a GI-safe derivative of aspirin.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Antibe Therapeutics Inc

Price: 0.42 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $148.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346;...

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive...

on 04/07/2020

2 min read